RxDoctor Payments Data

Mark Kostin, MD

Internal Medicine · Brooklyn, NYNPI 1790797322

Payments from drug & device makers

$862in general payments, 2019–2025

Across 21 payments — averaging $41.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$626
  • AbbVie$71
  • Avanir Pharmaceuticals, Inc.$41
  • Amgen$29
  • Amarin Pharma, Inc.$25
  • Lundbeck LLC$20
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$862100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merz North America, Inc.10$626
AbbVie(2 entities)3$71
Avanir Pharmaceuticals, Inc.2$41
Amgen1$29
Amarin Pharma, Inc.1$25
Lundbeck LLC1$20
Galderma Laboratories, L.p.1$20
Eisai Inc.1$17
Promius Pharma LLC1$14

How this compares

$862 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$27,794
Medicare patients
19
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DilaudidHydromorphone Hcl16$14,955
JanuviaSitagliptin Phosphate19$10,769
VascepaIcosapent Ethyl19$6,699
JardianceEmpagliflozin11$6,611
VytorinEzetimibe/Simvastatin12$4,634
HyzaarLosartan/Hydrochlorothiazide12$3,336
Dexlansoprazole DrDexlansoprazole15$2,357
Oxycodone Hcl83$1,879
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen38$1,544
SynthroidLevothyroxine Sodium14$1,127
Albuterol Sulfate HfaAlbuterol Sulfate23$890
Lisinopril70$565
Diclofenac Sodium18$486
Metoprolol Succinate27$334
Clonazepam31$305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$71$1,12714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →